Stoke Therapeutics (STOK) News
NASDAQ: STOKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
26.81-0.12 (-0.45%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
STOK news summary
We found 4 recent headlines mentioning Stoke Therapeutics (STOK): 0 in the past week and 2 in the past 30 days, most often from Nasdaq, Business Wire. For price context, STOK is down 0.45% at $26.81. The most recent story, "Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates", was published by Nasdaq on Oct 29, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Stoke Therapeutics headlines
- Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business UpdatesStoke Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical programs. The company had $358.8 million in cash, cash…Nasdaq
- Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business UpdatesBEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and…Business Wire
- Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial UpdatesBEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and…Business Wire
- Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue EstimatesStoke Therapeutics (STOK) delivered earnings and revenue surprises of -13.42% and +69.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqSTOK, IBRX